Ignite Creation Date:
2024-05-05 @ 11:54 AM
Last Modification Date:
2024-10-26 @ 9:15 AM
Study NCT ID:
NCT00165620
Status:
COMPLETED
Last Update Posted:
2010-01-29
First Post:
2005-09-12
Brief Title:
A Randomized Open Parallel Optimal Injection Rate-Finding Study for E7337 in Dynamic CT of the Liver in Patients With Liver Disease
Sponsor:
Eisai Limited
Organization:
Eisai Inc
Study Overview
Official Title:
None
Status:
COMPLETED
Status Verified Date:
2010-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To establish the optimum injection rate for E7337 Iomeron 350 in dynamic CT in patients who have hepatic lesionsThe primary endpoint for efficacy is the contrast enhancement effect in the early arterial phase and the primary safety endpoints are warming sensation and vascular pain
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None